Welcome to our dedicated page for Archrock news (Ticker: $AROC), a resource for investors and traders seeking the latest updates and insights on Archrock stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Archrock's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Archrock's position in the market.
Archrock, Inc. (NYSE: AROC) reported strong first quarter 2024 results with revenue at $268.5 million, net income of $40.5 million, and adjusted EBITDA of $131.0 million. The company raised its 2024 adjusted EBITDA guidance to $510-540 million. Archrock's long-term debt decreased to $1.6 billion, with a leverage ratio of 3.2x. The company declared a quarterly dividend of $0.165 per share and repurchased common shares during the quarter. Shareholders can expect a quarterly dividend payment on May 14, 2024.
